Thalidomide, Drug Safety, and Off-label Prescribing: Lessons Learned From Celgene's Settlement
JAMA Oncol
.
2018 Jul 1;4(7):915-916.
doi: 10.1001/jamaoncol.2018.0808.
Authors
Y Tony Yang
1
,
Brian Chen
2
,
Charles L Bennett
3
4
Affiliations
1
Department of Health Administration and Policy, George Mason University, Fairfax, Virginia.
2
Department of Health Services Policy and Management, University of South Carolina, Columbia.
3
Center for Medication Safety and Efficacy, University of South Carolina, Columbia.
4
Department of Clinical Pharmacy and Outcomes Science, University of South Carolina, Columbia.
PMID:
29801064
DOI:
10.1001/jamaoncol.2018.0808
No abstract available
MeSH terms
Biomarkers, Pharmacological
Humans
Off-Label Use / standards*
Thalidomide / adverse effects
Thalidomide / pharmacology*
Thalidomide / therapeutic use*
Substances
Biomarkers, Pharmacological
Thalidomide